相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cholesterol-Lowering Agents PCSK9 Inhibitors Today and Tomorrow
Robert S. Rosenson et al.
CIRCULATION RESEARCH (2019)
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
Dave L. Dixon et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial
Yundai Chen et al.
DIABETES OBESITY & METABOLISM (2019)
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
J. Wouter Jukema et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Stephen J. Nicholls
CURRENT CARDIOLOGY REPORTS (2019)
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial
Michael Szarek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Marc S. Sabatine et al.
CIRCULATION (2018)
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
Robert R. Henry et al.
DIABETES OBESITY & METABOLISM (2018)
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
Kausik K. Ray et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
Ye-Xuan Cao et al.
DIABETES OBESITY & METABOLISM (2018)
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Gerald F. Watts et al.
EUROPEAN HEART JOURNAL (2018)
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Yehuda Handelsman et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
Henry N. Ginsberg et al.
DIABETES THERAPY (2018)
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
Henry N. Ginsberg et al.
DIABETES THERAPY (2018)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca et al.
CIRCULATION (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program
Robert M. Stoekenbroek et al.
FUTURE CARDIOLOGY (2018)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
Luiz Sergio F. de Carvalho et al.
DIABETES CARE (2018)
Cognitive Function in a Randomized Trial of Evolocumab
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
Aris Karatasakis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis
Masa-aki Kawashiri et al.
ATHEROSCLEROSIS (2017)
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
B. Cariou et al.
DIABETES & METABOLISM (2017)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
Helen M. Colhoun et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Rainer Schulz et al.
BASIC RESEARCH IN CARDIOLOGY (2015)
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Joseph L. Goldstein et al.
CELL (2015)
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study
Dirk J. Blom et al.
CIRCULATION RESEARCH (2015)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary
Terry A. Jacobson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
分享论文
